Optimal Surveillance Strategies for Barrett's Esophagus Based

on Segment Length and Dysplasia Grade: A Cost-Effectiveness

Study

Akiko Kowada, MD, PhD[1,2]

1 Department of Occupational Health, Kitasato University Graduate School of

Medical Sciences, Kanagawa, Japan

2 Advanced Research Promotion Center, Health Sciences University of

Hokkaido, Hokkaido, Japan

ORCID: https://orcid.org/0000-0001-5200-4300

Correspondence to: Akiko Kowada (email: kowadaa@gmail.com)

Abstract

The risk of esophageal adenocarcinoma (EAC) in Barrett's esophagus (BE)

varies substantially by segment length and dysplasia grade. This study

evaluated the cost-effectiveness and health impacts of dysplasia-stratified EAC

surveillance strategies for the Japanese BE population. A state-transition model

was developed comparing endoscopy, sponge test, breath test, and miRNA test

with no surveillance from a healthcare payer perspective over a lifetime.

Non-invasive strategies were assessed as primary surveillance tools, with

positive results triggering confirmatory endoscopy, and a scenario analysis

evaluated AI-assisted endoscopy. Five BE populations of 50-year-old individuals

were modeled: ultra-short segment BE (USSBE), short-segment BE (SSBE),

long-segment nondysplastic BE (LSBE-NDBE), LSBE with low-grade dysplasia

(LSBE-LGD), and LSBE with high-grade dysplasia (LSBE-HGD). Each modality

was evaluated at surveillance intervals of 1, 2, 3, 4, 5, or 10 years. Primary

outcomes included net monetary benefits, costs, quality-adjusted life-years,

incremental cost-effectiveness ratios, and EAC deaths, with sensitivity analyses

assessing parameter uncertainty. Surveillance was not cost-effective for

USSBE, SSBE, or LSBE-NDBE. For LSBE-LGD, annual endoscopy was most

cost-effective, averting 83 EAC deaths per 10,000 individuals, while for

LSBE-HGD, annual breath testing was most cost-effective, averting 295 deaths.

These findings support dysplasia-specific surveillance in LSBE with implications

for global surveillance practice.

Key words: Barrett's esophagus; esophageal adenocarcinoma; dysplasia;

breath test; artificial intelligence-assisted endoscopy; health economics

1. Introduction

Barrett's esophagus (BE) is the principal precursor to esophageal adenocarcinoma (EAC), a malignancy with rising incidence and poor prognosis when diagnosed at advanced stages. Globally, EAC accounted for approximately 85,700 new cases in 2020, representing about 14% of all esophageal cancers, with the highest incidence observed in high-income regions such as North America, Western and Northern Europe, and Australia [1]. EAC began increasing sharply in Europe and the United States in the 1960s, marking the beginning of a rapid epidemiological transition [2]. In contrast, EAC remains relatively uncommon across Asia; however, the prevalence of BE has increased in several East Asian countries over the past two decades. In Japan, although squamous cell carcinoma remains predominant, the incidence of EAC has shown a gradual upward trend, suggesting that Japan may be entering a phase similar to that experienced by Western countries several decades earlier [3].

In Western countries, major gastroenterological societies —including the American College of Gastroenterology (ACG) [4], the American Society for

Gastrointestinal Endoscopy (ASGE) [5], and the British Society of

Gastroenterology (BSG) [6]—recommend structured endoscopic surveillance

for patients with BE. Surveillance intervals are primarily determined by

dysplasia grade, with segment length used to further refine intervals in

nondysplastic BE (NDBE). Alongside these guideline-based strategies, several

emerging technologies aim to enhance early detection of dysplasia and EAC.

These innovations serve two complementary roles: improving the diagnostic

performance of endoscopy, exemplified by artificial Intelligence (AI)-assisted

systems capable of real-time identification of subtle neoplastic changes [7]; and

reducing the burden of endoscopic examinations through minimally invasive

pre-endoscopic triage tools such as sponge-based cell-collection devices (e.g.,

Cytosponge) [8], breath-analysis platforms that detect volatile organic

compounds [9], and circulating biomarker assays including miRNA-based tests

[10].

In Japan, however, a standardized national surveillance framework for BE has

not been established. Although BE is frequently detected in Japan, surveillance

practices vary widely among institutions, and most cases represent

ultrashort-segment BE (USSBE) [3]. This high detection rate reflects Japan's

sensitive and precise endoscopic diagnostic practices, supported by a broader

endoscopic definition that classifies any visible columnar epithelium as BE.

Recent epidemiological analyses suggest that the incidence of EAC in Japan is

projected to increase in the coming decades [3]. Japan has long maintained a

nationwide endoscopic screening program for gastric cancer, providing regular

opportunities for incidental detection of esophageal neoplasia among individuals

over 50 years of age. As gastric cancer incidence continues to decline due to

decreasing *Helicobacter pylori* infection rates and widespread eradication

therapy [11], accompanied by a marked increase in reflux esophagitis, the

current screening system is expected to be simplified. This may reduce

opportunities for incidental EAC detection, even if gastric cancer surveillance is

maintained after *H. pylori* eradication. Consequently, establishing a dedicated

and evidence-based surveillance strategy for BE has become increasingly

important.

Given the rising prevalence of BE, the anticipated increase in EAC incidence,

and the absence of a unified surveillance strategy in Japan, the

cost-effectiveness of stratified EAC surveillance approaches warrants rigorous

evaluation. Therefore, the aim of this study is to evaluate the cost-effectiveness

of optimal stratified EAC surveillance strategies for the BE population in Japan,

with surveillance intervals defined by segment length and dysplasia grade.

2. Methods

2.1 Model Overview

We developed a state-transition model to evaluate the cost-effectiveness of

stratified surveillance strategies for EAC among individuals with BE in Japan.

Five BE subpopulations were modeled independently based on segment length

and dysplasia grade: ultra-short segment BE (USSBE), short-segment BE

(SSBE), long-segment BE (LSBE) without dysplasia (LSBE-NDBE), LSBE with

low-grade dysplasia (LSBE-LGD), and LSBE with high-grade dysplasia (LSBE-

HGD) (Figure 1). Each subgroup was simulated separately to reflect its distinct

annual incidence of EAC [12,13].

The model followed a hypothetical cohort of 50-year-old individuals with BE

from a healthcare payer perspective over a lifetime. Age 50 was selected

because it approximates the median age at BE diagnosis and allows evaluation

of lifetime surveillance benefits. Surveillance strategies included conventional

endoscopy, sponge test, breath test, and miRNA test, each evaluated at

intervals of 1, 2, 3, 4, 5, or 10 years. Non-invasive strategies were modeled as

primary surveillance tools followed by confirmatory endoscopy, and a

no-surveillance strategy served as the reference comparator. A one-year cycle

length with half-cycle correction was applied, and both costs and

quality-adjusted life-years (QALYs) were discounted at 3% annually.

2.2 Model Structure

Five independent Markov models were constructed, one for each BE subgroup,

to reflect subgroup-specific EAC incidence without assuming unobserved

natural-history transitions. Individuals entered the model in their corresponding

BE health state (NDBE, LGD, or HGD), underwent surveillance according to the

assigned strategy, and remained in that state unless they developed EAC or

died.

No transitions between BE states were assumed because the model relied

solely on observed EAC incidence and mortality rather than hypothetical

natural-history progression pathways. No preclinical disease state or interval

cancer construct was included; all cancers were assumed to occur and be

diagnosed within the same annual cycle. Mortality incorporated stage-specific

EAC survival [14] and background mortality from Japanese life tables [15].

Primary outcomes included net monetary benefits (NMBs), costs, QALYs,

incremental cost-effectiveness ratios (ICERs), and EAC deaths. A schematic

representation of health states and allowable transitions is shown in Figure 2.

2.3 Surveillance Strategies

Four surveillance modalities were evaluated: conventional endoscopy, sponge

test, breath test, and miRNA test. Each modality was assessed at surveillance

intervals of 1, 2, 3, 4, 5, or 10 years, with no surveillance as the reference.

AI-assisted endoscopy was evaluated in scenario analyses as an enhanced

form of conventional endoscopy.

Conventional endoscopy represented the current standard of care in Japan.

Sponge test, breath test, and miRNA test were modeled as non-invasive

primary surveillance tools. A positive non-endoscopic test triggered confirmatory

endoscopy and subsequent management according to stage-specific treatment

pathways in the Japanese Guidelines for the Diagnosis and Treatment of

Esophageal Cancer [16]. Individuals with negative results continued routine

surveillance at the assigned interval.

2.4 Diagnostic Performance

Sensitivity and specificity for conventional endoscopy were obtained from

meta-analyses and large observational cohorts [17]. Sensitivity and specificity

for sponge test, breath test, miRNA test, and AI-assisted endoscopy were

extracted from published studies [8,9,10,18].

False-negative results were modeled as cancers diagnosed clinically within the

same cycle, with stage distribution based on clinically detected EAC. Adherence

rates for conventional endoscopy, AI-assisted endoscopy, and breath test were

obtained from published sources [19], whereas adherence for sponge test and

miRNA test was assumed. All adherence parameters were varied widely (10–

90%) in sensitivity analyses.

2.5 Model Inputs

Model inputs included subgroup-specific annual EAC incidence [12,13],

diagnostic performance parameters, costs, health-state utilities, and mortality

rates. Annual EAC incidence was assigned separately for each BE subgroup

(USSBE, SSBE, LSBE-NDBE, LSBE-LGD, LSBE-HGD). Sensitivity, specificity,

and adherence were assigned independently for each surveillance modality

[8,9,10,17,18]. Costs reflected testing and cancer treatment expenditures [20].

Health-state utilities were derived from published literature [21,22].

Stage-specific EAC survival was based on Japanese data [14], and background

mortality was derived from Japanese life tables [15]. Costs and QALYs were

discounted at 3% annually [23].

2.5.1 Costs

Costs were derived from the Japanese national fee schedule [20] and converted

to U.S. dollars using the 2024 OECD purchasing power parity exchange rate

(95.1 yen per US$1) [24]. Costs for sponge test, breath test, AI-assisted

endoscopy, and miRNA test were not available in Japan and were therefore

treated as assumptions, with ranges explored in sensitivity analyses.

2.5.2 Health-State Utilities

Utilities were assigned to mutually exclusive health states representing the

clinical course of BE and EAC, including NDBE, LGD, HGD, four stage-specific

EAC states (I–IV), and three post-treatment states [21,22]. Death was modeled

as an absorbing state. Utility values were derived from published literature and

discounted at 3% [23].

2.6 Base-Case Analysis

The base-case analysis estimated costs, QALYs, ICERs, and NMBs. Strategies

were ordered by increasing QALYs, and extended dominance was applied

when appropriate. A willingness-to-pay threshold of US$50,000 per QALY

gained was used to determine cost-effectiveness [25].

2.7 Markov Cohort Analyses

Using a Markov cohort model, we estimated, for each surveillance strategy, the

cumulative 10-year and lifetime numbers of EAC deaths averted and the

cumulative 10-year and lifetime additional costs per EAC death averted,

compared with no surveillance. Analyses were conducted separately for

hypothetical cohorts of 10,000 LSBE-LGD patients and 10,000 LSBE-HGD

patients aged 50 years.

For each cohort, EAC deaths averted per 10,000 patients were calculated by

multiplying the difference in the cumulative probability of EAC death between

each surveillance strategy and no surveillance by 10,000. Additional costs per

EAC death averted were calculated by multiplying the difference in total

discounted costs between each surveillance strategy and no surveillance by

10,000 and dividing this value by the number of EAC deaths averted in the

corresponding 10,000-patient cohort.

2.8 Scenario Analyses

216 Scenario analyses evaluated AI-assisted endoscopy by substituting its

217 diagnostic performance parameters for those of conventional endoscopy within

218 each model. This approach allowed us to explore how improvements in

219 sensitivity and specificity attributable to AI would influence overall

220 cost-effectiveness across the surveillance strategies.

2.9 Sensitivity Analyses

One-way sensitivity analyses varied key clinical and economic parameters

across plausible ranges, including test sensitivity and specificity, surveillance

and treatment costs, health-state utilities, and subgroup-specific EAC incidence.

We also varied the starting age of surveillance from 40 to 80 years to evaluate

how age at initiation influenced cost-effectiveness outcomes. Deterministic

results were summarized using tornado diagrams.

A probabilistic sensitivity analysis was conducted using 10,000 Monte Carlo

simulations. Parameter uncertainty was represented using beta distributions for

test performance, subgroup-specific EAC incidence, and utilities, and gamma

distributions for costs. For each simulation, lifetime costs and QALYs were

recalculated, and cost-effectiveness acceptability curves were generated at a

willingness-to-pay (WTP) threshold of US$50,000 per QALY gained.

All analyses were conducted using TreeAge Pro 2026 (TreeAge Software,

Williamstown, MA). This economic evaluation followed the CHEERS 2022

reporting guidelines [26].

2.10 Model Validation

Model validation included face, internal, and external validation. Face validation

assessed whether the model structure, assumptions, and parameter inputs

were consistent with established frameworks for BE and EAC modeling. Internal

validation evaluated whether simulated transitions, incidence patterns, and

long-term outcomes behaved as expected across all five BE subgroups.

External validation compared model-generated estimates of EAC incidence,

stage distribution, and survival with published epidemiologic data. These checks

supported the credibility of the model for evaluating stratified surveillance

strategies.

3. Results

3.1 Base-case results

Base-case outcomes differed markedly across BE subgroups, driven primarily

by variation in annual EAC incidence.

USSBE

No surveillance was the preferred strategy, yielding the highest NMB

(US$869,600) (Table S1). Annual endoscopy increased costs substantially

(US$3,942 vs US$28) with only negligible QALY gains, lowering NMB to

US$865,697. Annual breath test and annual miRNA test produced even lower

NMBs.

SSBE

No surveillance again produced the highest NMB (US$950,019) (Table S2).

Annual endoscopy increased costs (US$4,117 vs US$225) with minimal QALY

improvement, reducing NMB to US$946,232. Across both short-segment

groups, surveillance strategies increased costs with only marginal benefits and

were not cost-effective at a WTP of US$50,000 per QALY.

LSBE-NDBE

No surveillance remained the preferred strategy (NMB US$938,821) (Table S3,

Figure 3A). Annual endoscopy raised costs (US$5,484 vs US$1,770) and

modestly improved QALYs, but resulted in a lower NMB (US$935,939). Annual

breath test and annual miRNA test yielded even lower NMBs. None of the

surveillance strategies were cost-effective.

LSBE-LGD

Annual endoscopy was the most cost-effective strategy, producing the highest

NMB (US$841,993) (Table S4, Figure 3B). Although no surveillance had lower

costs, it also produced fewer QALYs, resulting in a slightly lower NMB. Annual

breath test and annual miRNA test generated marginally higher QALYs but

substantially lower NMBs, indicating that their additional benefits did not justify

their higher costs.

LSBE-HGD

Annual breath test was the preferred strategy, with the highest NMB

(US$598,066) and an ICER of US$16,318 per QALY gained (Table S5, Figure

3C). Annual miRNA test produced the highest QALYs but was not cost-effective

due to its high ICER and lower NMB.

Overall

Surveillance was not cost-effective in low-risk subgroups (USSBE, SSBE,

LSBE-NDBE). In contrast, annual endoscopy for LSBE-LGD and annual breath

test for LSBE-HGD offered the greatest value in higher-risk populations.

3.2 EAC deaths averted and additional costs per death averted

EAC deaths averted and additional costs per EAC death averted were

evaluated for 10,000 LSBE-LGD and 10,000 LSBE-HGD patients over 10 years

and a lifetime.

In LSBE-LGD, annual endoscopy prevented 24 EAC deaths within 10 years and

83 EAC deaths over a lifetime (Table 2, Figure S6), with lifetime additional costs

of US$349,308 per EAC death averted (Table 3, Figure S8). Annual breath test

and annual miRNA test prevented slightly more EAC deaths (92 and 97 lifetime

deaths, respectively) but required substantially higher additional costs per EAC

death averted.

In LSBE-HGD, annual breath test prevented 209 EAC deaths within 10 years

and 295 deaths over a lifetime (Table 2, Figure S7), costing US$5,006 over 10

years but ultimately saving US$1,394 over a lifetime per EAC death averted

(Table 3, Figure S9). Although annual miRNA test prevented the most deaths

(311 over a lifetime), it did so at substantially higher additional costs per EAC

death averted. These findings indicate that the absolute mortality benefit of

surveillance rises sharply with baseline EAC incidence, with annual breath test

offering the most favorable balance of EAC death reduction and cost in HGD.

3.3 Scenario analyses

When AI-assisted endoscopy was evaluated as an alternative to conventional

endoscopy, no surveillance remained cost-effective in USSBE, SSBE, and

LSBE-NDBE at a WTP threshold of US$50,000 per QALY (Table S5–S8).

In LSBE-LGD, annual AI-assisted endoscopy yielded the highest NMB

(US$842,747), whereas in LSBE-HGD, annual breath test following AI-assisted

endoscopy produced the highest NMB (US$603,334) (Table S9 and Table S10).

These effects were driven by the higher sensitivity and specificity of AI-assisted

endoscopy, which increased early detection while reducing false positives in

higher-risk subgroups.

3.4 Sensitivity analyses

One-way sensitivity analyses indicated that cost-effectiveness was primarily

driven by subgroup-specific EAC incidence and test adherence.

In LSBE-LGD, annual endoscopy became cost-effective relative to no

surveillance when annual EAC incidence exceeded 0.009 (Figure S1).

In LSBE-HGD, annual breath test was favored over annual endoscopy when

endoscopy adherence exceeded 83.5% and breath-test adherence remained

below 88.8% (Figure S2). Annual miRNA test became more cost-effective than

annual breath test when breath-test adherence fell below 83.7% (Figure S3).

Cost-effectiveness acceptability curves showed a 79% probability that no

surveillance is cost-effective in LSBE-NDBE (Figure 4A), a 36% probability that

annual endoscopy is cost-effective in LSBE-LGD (Figure 4B and Figure S4),

and a 29% probability that annual breath test is cost-effective in LSBE-HGD

(Figure 4C and Figure S5) at a WTP threshold of US$50,000 per QALY gained.

Robustness of Findings Across Subgroups

Findings on which subgroups benefit from surveillance were generally robust

across sensitivity analyses, with low-risk subgroups consistently favoring no

surveillance. Although the overall decision to perform surveillance remained

stable, the relative ranking of surveillance strategies within higher-risk

subgroups (LGD or HGD) shifted depending on subgroup-specific EAC

incidence and test adherence.

4. Discussion

4.1 Principal Findings

This study demonstrates that stratified surveillance strategies for BE, defined by

segment length and dysplasia grade, provide the most cost-effective approach

for the Japanese population. By incorporating Japan-specific incidence data for

USSBE and SSBE and applying Western subgroup-specific incidence estimates

for LSBE (NDBE, LGD, and HGD) derived from meta-analyses [12], we

developed a transparent incidence-based framework across five clinically

distinct subgroups. Using this framework, we identified that annual endoscopy is

the optimal strategy for patients with LGD, whereas annual breath test is the

most cost-effective strategy for those with HGD.

Across subgroups, differences in EAC deaths averted closely mirrored

differences in baseline EAC incidence, indicating that incidence is the primary

determinant of the preferred surveillance strategy. As incidence increased, the

optimal strategy shifted in a clear stepwise pattern: surveillance offered limited

value in USSBE, SSBE, and LSBE-NDBE; annual endoscopy became optimal

in LSBE-LGD; and annual breath testing became optimal in LSBE-HGD. This

pattern reflects the strong dependence of surveillance benefit on underlying

cancer risk and the diagnostic performance of available tests.

Because AI-assisted endoscopy improves sensitivity and specificity from 75%

and 70% to 93% and 78%, respectively, it directly replaces standard endoscopy

in the incidence range where endoscopic surveillance was previously optimal.

This shift illustrates how improvements in test accuracy can move the incidence

thresholds that define the preferred strategy, further reinforcing the

transparency and adaptability of an incidence-based modeling approach.

To our knowledge, this study provides the first fully integrated, risk-stratified

cost-effectiveness evaluation of EAC surveillance in BE worldwide. It also

incorporates both conventional and AI-assisted endoscopic modalities, as well

as emerging non-endoscopic approaches. Importantly, because LSBE

incidence inputs are derived from Western literature, the model is not limited to

Japan; substituting region-specific cost parameters would allow direct

application to Western healthcare settings.

Japan provides a unique context for evaluating surveillance strategies because

it has one of the world's highest proportions of ultrashort-segment BE [3] and a

lower baseline incidence of EAC compared with Western countries. Historically,

early detection of EAC in Japan has relied on incidental findings during gastric

cancer screening, routine health checkups, and other clinical encounters. As

opportunities for incident detection are expected to decline [3], risk-stratified

surveillance becomes increasingly important for maintaining early-stage

diagnosis while avoiding unnecessary procedures in low-risk groups. Emerging

technologies such as breath test and AI-assisted endoscopy may further

enhance surveillance efficiency, particularly in intermediate- and high-risk

groups. Overall, this study provides a policy-relevant foundation for developing

surveillance recommendations tailored to Japan while offering a generalizable

framework applicable to Western populations.

4.2 Comparison with Previous Studies

Two cost-effectiveness analyses have previously evaluated BE surveillance.

Kastelein et al. demonstrated that surveillance with endoscopic mucosal

resection and radiofrequency ablation for HGD or early EAC, and

oesophagectomy for advanced EAC, is cost-effective every 5 years for NDBE

and every 3 years for LGD, based on a Dutch healthcare perspective and a

willingness-to-pay threshold of €35,000 per QALY [27]. Vissapragada et al.

further identified risk-stratified surveillance strategies as the most cost-effective,

showing that biennial surveillance for long-segment BE (>2 cm) and 12-month

surveillance for LGD provided the best value, thereby confirming the utility of

dysplasia-based risk stratification in Australia [28]. These cost-effectiveness

models simulated the natural history from BE to EAC and required numerous

structural assumptions, including progression rates, dwell times, and transition

probabilities, that vary widely across studies and contribute to inconsistent

estimates of surveillance benefit, particularly in NDBE. Our findings additionally

identified annual breath test for LSBE-HGD and annual endoscopy for

LSBE-LGD as the most cost-effective strategies, and showed that AI-assisted

endoscopy can serve as a cost-effective alternative to conventional endoscopy.

Our study also employs an incidence-based framework anchored to empirically

observed annual EAC incidence, avoiding assumptions about preclinical

disease dynamics and providing a more transparent representation of cancer

risk across clinically distinct subgroups.

Evaluating the cost-effectiveness of surveillance for USSBE and SSBE is

essential because these segments represent the majority of BE cases in Japan

[3]. This study is the first to demonstrate limited cost-effectiveness of

surveillance for NDBE—including USSBE and SSBE—when empirical

incidence is applied without additional structural assumptions. Our model also

incorporates Western dysplasia-specific incidence estimates for LSBE [13],

reflecting the limited availability of Japanese data and anticipating future

increases in LGD and HGD, thereby supporting applicability to Western

populations as well. Furthermore, our evaluation of emerging technologies,

such as breath test and AI-assisted endoscopy, extends previous work by

demonstrating their potential value in Japan and in higher-incidence settings

[9,18]. Non-endoscopic examinations may further alleviate the surveillance

burden for individuals with BE, particularly in settings where frequent endoscopy

is difficult to sustain.

4.3 Strengths and Limitations

This study has several methodological strengths. First, it employs an

incidence-based framework that does not rely on unobservable progression

states or assumptions about transitions between nondysplastic BE, dysplasia,

and preclinical cancer. By grounding the model in empirically observed annual

EAC incidence for each subgroup, the analysis avoids the structural uncertainty

inherent in traditional multistate models and provides a transparent

representation of cancer risk. Second, evaluating five clinically distinct BE

subgroups independently allows surveillance strategies to be compared within

risk strata, clarifying why surveillance yields limited benefit in low-risk groups

and substantial benefit in high-risk groups. Third, the model incorporates

modality-specific test performance and applies consistent probability

distributions across parameters, enhancing transparency and reducing reliance

on unverifiable assumptions. Finally, using a fixed cohort of 10,000 individuals

per subgroup ensures comparability across analyses, allowing surveillance

strategies to be evaluated independently of uncertain subgroup size estimates.

This study also has limitations. First, although Japan has published EAC

incidence estimates for USSBE, SSBE, and LSBE overall [12],

dysplasia-stratified incidence estimates are not available. Further research will

be needed to establish reliable incidence estimates for LSBE subgroups,

including separate estimates for NDBE, LGD, and HGD. Second, reliable data

on the population size of each BE subgroup in Japan are lacking [3], which

prevented estimation of national-level impacts and necessitated the use of a

fixed cohort size for subgroup analyses. Third, several evaluated modalities,

such as sponge test, breath test, miRNA test, and AI-assisted endoscopy, are

not yet reimbursed under the Japanese national insurance system, requiring

cost assumptions that may differ from future reimbursement prices. Fourth, test

performance parameters were derived from heterogeneous Western studies

[8,9,10,17,18], and real-world performance in Japan may differ. However, this

limitation was addressed by conducting sensitivity analyses using wide

parameter ranges. Finally, patient burden associated with undergoing

surveillance tests was not incorporated into the model, although it is an

important consideration, particularly for non-invasive modalities.

4.4 Clinical and Policy Implications

The findings of this study have important implications for clinical practice and

health policy. First, the clear stratification of surveillance benefit across Barrett's

esophagus subgroups supports a shift toward risk-based surveillance rather

than uniform intervals. The limited value of surveillance in USSBE, SSBE, and

LSBE-NDBE suggests that routine endoscopic surveillance may not be justified

for these low-risk groups in Japan. Conversely, the strong cost-effectiveness

observed in LSBE-LGD and LSBE-HGD reinforces the need for timely and

intensive surveillance in higher-risk patients, consistent with their substantially

elevated incidence of EAC.

Second, the results highlight the potential role of emerging non-endoscopic

technologies, particularly breath test, which demonstrated favorable

cost-effectiveness in high-risk groups. These modalities may reduce the burden

of repeated endoscopy, improve patient acceptability, and expand access to

surveillance in settings with limited endoscopic capacity. AI-assisted endoscopy

may further enhance diagnostic accuracy and efficiency as evidence

accumulates [7]. AI-assisted endoscopy, which surpasses the diagnostic

performance of conventional endoscopy and offers greater cost-effectiveness, is

likely to replace standard endoscopy in the incidence range where it is currently

preferred, further improving the efficiency of surveillance programs.

Third, future integration of individualized risk-prediction tools could further

enhance precision. Although segment length and dysplasia grade remain the

strongest determinants of cancer risk, additional factors, such as age, sex,

obesity, and GERD severity [29,30], could refine risk stratification and guide

personalized surveillance intensity.

Fourth, the incidence-based and hybrid structure of the model, which uses

Japan-specific incidence for USSBE and SSBE and Western subgroup-specific

incidence for LSBE, ensures that the framework is not restricted to Japan and

can be directly applied to other regions, including Western countries, by

substituting local cost parameters. This generalizability enhances the relevance

of the findings beyond Japan and provides a foundation for international

comparisons of surveillance strategies.

Fifth, structured risk-stratified surveillance will become increasingly important for

maintaining early-stage EAC detection while avoiding unnecessary procedures

in low-risk groups, particularly as EAC incidence is expected to rise in Japan.

Policymakers may consider incorporating these findings into future national

guidelines to optimize resource allocation and improve patient outcomes.

Finally, integrating BE/EAC surveillance into Japan's upper gastrointestinal

screening system and post–*H. pylori* eradication surveillance could allow these

pathways to be restructured into a more comprehensive upper gastrointestinal

screening framework. Such integration may improve efficiency in lower-risk

populations while maintaining appropriate monitoring for higher-risk patients.

5. Conclusions

This study demonstrates that the value of surveillance for Barrett's esophagus

varies substantially across subgroups defined by segment length and dysplasia

grade. Annual endoscopy is cost-effective for LGD, whereas annual breath test

is cost-effective for HGD. In contrast, surveillance offers limited value for NDBE.

These findings support prioritizing surveillance resources for higher-risk groups

while avoiding unnecessary procedures in low-risk populations.

By grounding the model in empirically observed cancer incidence and avoiding

assumptions about unobservable progression states, this study provides a

transparent and reproducible framework for evaluating surveillance strategies.

Its incidence-based Markov structure makes the framework broadly

generalizable and applicable beyond Japan, including to Western healthcare

systems.

Emerging technologies, including AI-assisted endoscopy, sponge test, breath

test, and miRNA test, may further enhance the cost-effectiveness of

surveillance, particularly in intermediate- and high-risk groups. The

development of non-endoscopic procedures is also expected to reduce patient

burden and expand access to surveillance.

As EAC incidence is projected to rise in Japan, these findings offer timely,

population-specific evidence to guide future surveillance recommendations.

Adoption of dysplasia-stratified, incidence-aligned strategies may help optimize

resource allocation while maximizing clinical benefit in Japan and could serve

as a model for other regions with similarly low but increasing EAC incidence.

List of Abbreviations

AI: Artificial intelligence

BE: Barrett's esophagus

EAC: Esophageal adenocarcinoma

HGD: High-grade dysplasia

ICER: Incremental cost-effectiveness ratio

LGD: Low-grade dysplasia

LSBE: Long-segment Barrett's esophagus

miRNA: MicroRNA

NDBE: Nondysplastic Barrett's esophagus

NMB: Net monetary benefit

QALY: Quality-adjusted life-year

SSBE: Short-segment Barrett's esophagus

USSBE: Ultrashort-segment Barrett's esophagus

Acknowledgments

None.

Data availability

All data used in this study are publicly available aggregated national statistics,

and no individual-level data were used.

Funding

This research received no specific grant from any funding agency in the public,

commercial, or not-for-profit sectors.

Competing interests

The author declares no competing interests.

Ethics statement

This study used publicly available, aggregated national statistics and did not

involve human subjects. Therefore, ethical approval was not required.

Author contributions

The author conceptualized the study, developed the model, conducted the

analysis, validated the model, interpreted the results, drafted the manuscript,

and revised the final version.

Reference

1. Morgan, E. et al. The global landscape of esophageal squamous cell
carcinoma and esophageal adenocarcinoma incidence and mortality in
2020 and projections to 2040: New estimates from GLOBOCAN 2020.
Gastroenterology **163**, 649–658.e2 (2022).
https://doi.org/10.1053/j.gastro.2022.05.054
2. Blot, W. J., Devesa, S. S., Kneller, R. W. & Fraumeni, J. F. Rising
incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA*
265, 1287–1289 (1991).

3.   Iijima, K. Epidemiology of Barrett's neoplasia in Japan. *Digestion* **107**, 5–
14 (2026). https://doi.org/10.1159/000548362

4.   Shaheen, N. J. et al. ACG clinical guideline: Diagnosis and management
of Barrett's esophagus. *Am. J. Gastroenterol.* **111**, 30–51 (2016).
https://doi.org/10.1038/ajg.2015.322

5.   Qumseya, B. et al. ASGE guideline on screening and surveillance of
Barrett's esophagus. *Gastrointest. Endosc.* **90**, 335–359.e2 (2019).
https://doi.org/10.1016/j.gie.2019.05.012

6.   Fitzgerald, R. C. et al. British Society of Gastroenterology guidelines on
the diagnosis and management of Barrett's oesophagus. *Gut* **63**, 7–42
(2014). https://doi.org/10.1136/gutjnl-2013-305372

7.   Hashimoto, R. et al. Artificial intelligence using convolutional neural
networks for real-time detection of early esophageal neoplasia in
Barrett's esophagus. *Gastrointest. Endosc.* **91**, 1264–1271.e1 (2020).
https://doi.org/10.1016/j.gie.2019.12.049

8.   Kakar, M. T. et al. Diagnostic test accuracy of Cytosponge–Trefoil Factor
3 for Barrett esophagus: A systematic review and meta-analysis. *JGH*
Open **9**, e70248 (2025). https://doi.org/10.1002/jgh3.70248

9.   Peters, Y. et al. Detection of Barrett's oesophagus through exhaled
breath using an electronic nose device. *Gut* **69**, 1169–1172 (2020).
https://doi.org/10.1136/gutjnl-2019-320273

10. Miyoshi, J. et al. Liquid biopsy to identify Barrett's oesophagus, dysplasia
and oesophageal adenocarcinoma: The EMERALD multicentre study.
Gut **74**, 169–181 (2025). https://doi.org/10.1136/gutjnl-2024-333364

11. Kowada, A. & Asaka, M. Economic and health impacts of introducing
Helicobacter pylori eradication strategy into national gastric cancer policy
in Japan: A cost-effectiveness analysis. *Helicobacter* **26**, e12837 (2021).
https://doi.org/10.1111/hel.12837

12. Fukuda, S. et al. Cancer risk by length of Barrett's esophagus in
Japanese population: A nationwide multicenter retrospective cohort
study. *J. Gastroenterol.* **59**, 887–895 (2024).
https://doi.org/10.1007/s00535-024-02139-2

13. Tan, J. et al. Incidence rates of Barrett's esophagus and esophageal
adenocarcinoma: A systematic review and meta-analysis. *iGIE* **3**, 92–103
(2024). https://doi.org/10.1016/j.igie.2024.01.001

14. Cancer Information Service, National Cancer Center Japan. Cancer
registry and statistics.
https://ganjoho.jp/reg_stat/statistics/stat/cancer/5_stomach.html
(Accessed 14 Feb 2026).
15. Ministry of Health, Labour and Welfare Japan. Vital statistics.
https://www.mhlw.go.jp/english/database/db-hw/vs01.html (Accessed 14
Feb 2026).
16. Japanese Esophageal Society. *Japanese Guidelines for the Diagnosis*
and Treatment of Esophageal Cancer 2022. Kanehara & Co. (2022).
17. Ishihara, R., Goda, K. & Oyama, T. Endoscopic diagnosis and treatment
of esophageal adenocarcinoma: Introduction of Japan Esophageal
Society classification of Barrett's esophagus. *J. Gastroenterol.* **54**, 1–9
(2019). https://doi.org/10.1007/s00535-018-1491-x
18. Guidozzi, N. et al. The role of artificial intelligence in the endoscopic
diagnosis of esophageal cancer: A systematic review and meta-analysis.
Dis. Esophagus **36**, doad048 (2023).
https://doi.org/10.1093/dote/doad048
19. Sijben, J. et al. The public's intended uptake of hypothetical esophageal
adenocarcinoma screening scenarios: A nationwide survey. *Am. J.*
Gastroenterol. **119**, 1802–1812 (2024).
https://doi.org/10.14309/ajg.0000000000002812
20. Igakutsushin-sya. *National Fee Schedule and Medical Insurance*
Reimbursement Table in Japan. Igakutsushin-sya (2025).
21. Bulamu, N. B. et al. Health-related quality of life associated with Barrett's
esophagus and cancer. *World J. Surg.* **43**, 1554–1562 (2019).
https://doi.org/10.1007/s00268-019-04936-w
22. Hur, C., Wittenberg, E., Nishioka, N. S. & Gazelle, G. S. Quality of life in
patients with various Barrett's esophagus associated health states.
Health Qual. Life Outcomes **4**, 45 (2006). https://doi.org/10.1186/1477-
7525-4-45
23. Baltussen, R. M. P. M. et al. *Making Choices in Health: WHO Guide to*
Cost-Effectiveness Analysis. World Health Organization (2003).
https://apps.who.int/iris/handle/10665/42699 (Accessed 14 Feb 2026).
24. Organisation for Economic Co-operation and Development (OECD).
Purchasing power parities and exchange rates.

https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm
(Accessed 14 Feb 2026).

25. Ministry of Health, Labour and Welfare Japan. Establishment of reference values for cost-effectiveness evaluation 2018. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000211609.pdf (Accessed 14 Feb 2026).

26. Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. *Value Health* **25**, 3–9 (2022). https://doi.org/10.1016/j.jval.2021.11.1351

27. Kastelein, F. et al. Surveillance in patients with long-segment Barrett's oesophagus: A cost-effectiveness analysis. *Gut* **64**, 864–871 (2015). https://doi.org/10.1136/gutjnl-2014-307197

28. Vissapragada, R. et al. Evaluating cost-effectiveness of 85 endoscopic surveillance strategies of nondysplastic Barrett's esophagus. *J. Gastroenterol. Hepatol.* (2026). https://doi.org/10.1111/jgh.70238

29. Antonios, K. et al. Risk factors for the development of Barrett's esophagus and esophageal adenocarcinoma: A systematic review and meta-analysis. *Cancer Rep.* **8**, e70168 (2025). https://doi.org/10.1002/cnr2.70168

30. Thrift, A. P. & Kendall, B. J. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma. *Gastrointest. Endosc. Clin. N. Am.* **36**, 49–68 (2026). https://doi.org/10.1016/j.giec.2025.05.006

 Table 1. Baseline estimates for selected variables

Variable	Baseline value	One-way sensitivity analysis range	Distribution	Reference
Probabilities				
Annual EAC incidence in USSBE	0.000032	0.0000066-0.00013	Beta	12
Annual EAC incidence in SSBE	0.00026	0.00011-0.00054	Beta	12
Annual EAC incidence in LSBE-NDBE	0.0021	0.0012-0.0029	Beta	13
Annual EAC incidence in LSBE-LGD	0.0116	0.0057-0.0175	Beta	13
Annual EAC incidence in LSBE-HGD	0.1416	0.1243-0.1589	Beta	13
Adherence rate (%)				
Endoscopy	78	10-100	Beta	19
AI-assisted endoscopy	78	10-100	Beta	19
Sponge test	75	10-100	Beta	19
Breath test	95	10-100	Beta	Assumption
miRNA test	95	10-100	Beta	Assumption
Sensitivity (%)				
Endoscopy	75	60-100	Beta	17
AI-assisted endoscopy	93	88-100	Beta	18
Sponge test	81	76-85	Beta	8
Breath test	91	84-95	Beta	9
miRNA test	95.8	89.8-98.4	Beta	10
Specificity (%)				
Endoscopy	70	55-95	Beta	17
AI-assisted endoscopy	78	53-94	Beta	18
Sponge test	89	82-93	Beta	8
Breath test	74	69-79	Beta	9
miRNA test	95.2	87.1-98.4	Beta	10
Costs (US$) US$1 = ¥95.1				
Endoscopy	234	117-468	Gamma	20

AI-assisted endoscopy	256	128-512	Gamma	Assumption
Sponge test	420	210-840	Gamma	Assumption
Breath test	60	30-120	Gamma	Assumption
miRNA test	700	350-1,400	Gamma	Assumption
EAC stage I treatment	7,361	3,681-14,722	Gamma	20
EAC stage II treatment	28,391	14,196-56,782	Gamma	20
EAC stage III treatment	10,515	5,258-21,030	Gamma	20
EAC stage IV treatment	21,030	10,515-42,060	Gamma	20
Health state utilities				
NDBE	0.93	0.88-0.96	Beta	
LGD	0.88	0.82-0.92	Beta	
HGD	0.82	0.75-0.88	Beta	
EAC stage I	0.78	0.72-0.84	Beta	
EAC stage II	0.72	0.65-0.78	Beta	
EAC stage III	0.62	0.55-0.70	Beta	21,22
EAC stage IV	0.50	0.40-0.60	Beta	
Post-treatment state NDBE	0.93	0.88-0.96	Beta	
Post-treatment state LGD	0.88	0.82-0.92	Beta	
Post-treatment state HGD	0.82	0.75-0.88	Beta	
Death	0	N/A	-	

680 AI, artificial intelligence; EAC, esophageal adenocarcinoma; NDBE,

681 non-dysplastic Barrett's esophagus; LGD, low-grade dysplasia; HGD,

682 high-grade dysplasia; USSBE, ultrashort-segment Barrett's esophagus; SSBE,

683 short-segment Barrett's esophagus; LSBE, long-segment Barrett's esophagus;

684 miRNA, microRNA; N/A, not applicable.

Table 2. EAC deaths averted per 10,000 LSBE-LGD and 10,000 LSBE-HGD patients over 10 years and over a lifetime

Strategy	LGD 10-year (n)	LGD Lifetime (n)	HGD 10-year (n)	HGD Lifetime (n)
Annual endoscopy	24	83	188	266
Annual breath test	26	92	209	295
Annual miRNA test	27	97	220	311

EAC, esophageal adenocarcinoma; LSBE, long-segment Barrett's esophagus; LGD, low-grade dysplasia; HGD, high-grade dysplasia.

Table 3. Additional costs per EAC death averted among 10,000 LSBE-LGD and 10,000 LSBE-HGD patients over 10 years and over a lifetime

Strategy	LGD 10-year (US$)	LGD Lifetime (US$)	HGD 10-year (US$)	HGD Lifetime (US$)
Annual endoscopy	643,748	349,308	-25,993	-26,146
Annual breath test	1,056,622	578,183	5,006	-1,394
Annual miRNA test	2,952,059	1,628,909	147,316	112,239

EAC, esophageal adenocarcinoma; LSBE, long-segment Barrett's esophagus; LGD, low-grade dysplasia; HGD, high-grade dysplasia.

Figure 1. Classification of Barrett's esophagus subtypes

Visual representation of Barrett's esophagus (BE) subtypes, categorized by
segment length and dysplasia status. The diagram distinguishes ultrashort-
segment BE (USSBE), short-segment BE (SSBE), long-segment BE (LSBE)
with nondysplastic BE (LSBE-NDBE), low-grade dysplasia (LGD), and high-
grade dysplasia (HGD).

Figure 2. State-transition diagram for Barrett's esophagus progression

Markov model structure illustrating disease progression and outcomes for patients with Barrett's esophagus. Health states include Barrett's esophagus, esophageal adenocarcinoma, post-treatment state, and death. Arrows indicate possible transitions between states, including progression to esophageal adenocarcinoma, treatment, and death.

Figure 3. Base-case results for LSBE subgroups

A. LSBE with nondysplastic Barrett's esophagus (LSBE-NDBE)

B. LSBE with low-grade dysplasia (LSBE-LGD)

C. LSBE with high-grade dysplasia (LSBE-HGD)

Base-case analysis comparing screening strategies in patients with LSBE, stratified by dysplasia status. Each panel presents incremental cost and effectiveness for evaluated screening strategies. The dashed line indicates the willingness-to-pay threshold of US$50,000 per QALY. Strategies on the cost-effectiveness frontier are considered undominated. LSBE, long-segment Barrett's esophagus.

Figure 4. Cost-effectiveness acceptability curves for LSBE subgroups

A. LSBE with nondysplastic Barrett's esophagus (LSBE-NDBE)

B. LSBE with low-grade dysplasia (LSBE-LGD)

C. LSBE with high-grade dysplasia (LSBE-HGD)

Curves show the probability that each screening strategy is cost-effective across a range of willingness-to-pay thresholds, based on probabilistic sensitivity analyses. Colors are consistent across all panels to represent the same screening strategies. LSBE, long-segment Barrett's esophagus.